Mesoblast Limited MSB.AX Stock
Mesoblast Limited Price Chart
Mesoblast Limited MSB.AX Financial and Trading Overview
| Mesoblast Limited stock price | 0.82 AUD |
| Previous Close | 1.05 AUD |
| Open | 1.05 AUD |
| Bid | 1.1 AUD x 0 |
| Ask | 1.1 AUD x 0 |
| Day's Range | 1.03 - 1.1 AUD |
| 52 Week Range | 0.61 - 1.33 AUD |
| Volume | 3.77M AUD |
| Avg. Volume | 1.57M AUD |
| Market Cap | 895.03M AUD |
| Beta (5Y Monthly) | 2.434099 |
| PE Ratio (TTM) | 0.31428573 |
| EPS (TTM) | -0.13 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.98 AUD |
MSB.AX Valuation Measures
| Enterprise Value | 846.58M AUD |
| Trailing P/E | 0.31428573 |
| Forward P/E | -2.244898 |
| PEG Ratio (5 yr expected) | 3.47 |
| Price/Sales (ttm) | 117.98421 |
| Price/Book (mrq) | 1.6793895 |
| Enterprise Value/Revenue | 111.598 |
| Enterprise Value/EBITDA | -12.547 |
Trading Information
Mesoblast Limited Stock Price History
| Beta (5Y Monthly) | 2.434099 |
| 52-Week Change | 53.67% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.33 AUD |
| 52 Week Low | 0.61 AUD |
| 50-Day Moving Average | 1.02 AUD |
| 200-Day Moving Average | 0.97 AUD |
MSB.AX Share Statistics
| Avg. Volume (3 month) | 1.57M AUD |
| Avg. Daily Volume (10-Days) | 1.54M AUD |
| Shares Outstanding | 813.66M |
| Float | 612.47M |
| Short Ratio | N/A |
| % Held by Insiders | 12.05% |
| % Held by Institutions | 23.76% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -922.99% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -6.56% |
| Return on Equity (ttm) | -16.29% |
Income Statement
| Revenue (ttm) | 7.59M AUD |
| Revenue Per Share (ttm) | 0.01 AUD |
| Quarterly Revenue Growth (yoy) | -3.59% |
| Gross Profit (ttm) | -53361000 AUD |
| EBITDA | -67471000 AUD |
| Net Income Avi to Common (ttm) | -81425000 AUD |
| Diluted EPS (ttm) | 3.5 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 48.8M AUD |
| Total Cash Per Share (mrq) | 0.07 AUD |
| Total Debt (mrq) | 114.61M AUD |
| Total Debt/Equity (mrq) | 23.77 AUD |
| Current Ratio (mrq) | 1.138 |
| Book Value Per Share (mrq) | 0.655 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -60885000 AUD |
| Levered Free Cash Flow (ttm) | -50345700 AUD |
Profile of Mesoblast Limited
| Country | Australia |
| State | VIC |
| City | Melbourne |
| Address | 55 Collins Street |
| ZIP | 3000 |
| Phone | 61 3 9639 6036 |
| Website | https://www.mesoblast.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 77 |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Q&A For Mesoblast Limited Stock
What is a current MSB.AX stock price?
Mesoblast Limited MSB.AX stock price today per share is 0.82 AUD.
How to purchase Mesoblast Limited stock?
You can buy MSB.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mesoblast Limited?
The stock symbol or ticker of Mesoblast Limited is MSB.AX.
Which industry does the Mesoblast Limited company belong to?
The Mesoblast Limited industry is Biotechnology.
How many shares does Mesoblast Limited have in circulation?
The max supply of Mesoblast Limited shares is 1.01B.
What is Mesoblast Limited Price to Earnings Ratio (PE Ratio)?
Mesoblast Limited PE Ratio is now.
What was Mesoblast Limited earnings per share over the trailing 12 months (TTM)?
Mesoblast Limited EPS is -0.13 AUD over the trailing 12 months.
Which sector does the Mesoblast Limited company belong to?
The Mesoblast Limited sector is Healthcare.
Mesoblast Limited MSB.AX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| S&P/ASX 200 Net Total Rtn AXNT | 93030.3 AUD 61572.77 USD |
-0.38
|
— — | 92750.3 AUD 61387.45 USD | 93395.1 AUD 61814.22 USD | — - | — — |
| S&P/ASX 200 EQUAL WEIGHT AXEW | 1883.5 AUD 1246.61 USD |
-0.78
|
— — | 1876.4 AUD 1241.91 USD | 1898.4 AUD 1256.47 USD | — - | — — |
| S&P/ASX SMALL ORDINARIES AXSO | 3055.7 AUD 2022.44 USD |
-0.94
|
— — | 3042.1 AUD 2013.44 USD | 3084.6 AUD 2041.56 USD | — - | — — |
| S&P/ASX 300 AXKO | 7711.3 AUD 5103.78 USD |
-0.4
|
— — | 7688.2 AUD 5088.49 USD | 7743.1 AUD 5124.83 USD | — - | — — |
| ALL ORDINARIES AORD | 8014.4 AUD 5304.39 USD |
-0.44
|
— — | 7991.2 AUD 5289.03 USD | 8050.6 AUD 5328.35 USD | — - | — — |
- {{ link.label }} {{link}}